| Start | Name | Affiliation | Country | Title |
|---|---|---|---|---|
| Friday, 26 June 2026 | ||||
| 8:00 AM | Registration | |||
| 8:45 AM | Jakub Zieg, MD, PhD | University Hospital Motol, Prague | Czech Republic | Welcome |
| 8:50 AM | Kyle Wood, MD & Yaacov Frishberg, MD | University of Alabama, Birmingham & Shaare Zedek Medical Center | United States & Israel | Introduction |
| 9:00 AM | Peter C. Harris, PhD | Mayo Clinic, Rochester | United States | Is There Further Genetic Heterogeneity in PH? Lessons from Polycystic Kidney Disease |
| Session 1: From Metabolism to Disease: The Impact of Oxalate | ||||
| Chair: Todd Lowther, PhD Wake Forest University School of Medicine United States | ||||
| 9:25 AM | Ehud Ohana, PhD | Ben Gurion University of the Negev | Israel | Altered Metabolic Homeostasis Rewires Hepato-Renal Axis Signaling in Primary Hyperoxaluria Type 3 |
| 9:40 AM | Gerlineke Hawkins Van der Cingel, MBBS | Charité – Universitätsmedizin Berlin | Germany | Effect of Lumasiran in Hyperoxalaemic Patients on Maintenance Haemodialysis |
| 9:55 AM | Kyle Wood, MD | University of Alabama, Birmingham | United States | Mouse model of MASH |
| Oral Abstract Speed Round: | ||||
| 10:10 AM | Sonia Fargue, MD, PhD | University of Alabama, Birmingham | United States | Metabolic Dysfunction-Associated Steatotic Liver Disease in a Mouse Model of Primary Hyperoxaluria Type 1 |
| 10:17 AM | Megan Prochaska, MD, MPH | University of Chicago Medicine, Chicago | United States | The Oxalate and Citrate Association in Humans |
| 10:24 AM | Coffee Break | |||
| Session 2: From Bench to Bedside: PH2 and PH3 | ||||
| Chair: Hadas Shasha-Lavsky, MD Galilee Medical Center Israel | ||||
| 10:45 AM | Efrat Ben-Shalom, MD | Shaare Zedek Medical Center | Israel | What Have We Learned Since the Discovery of PH3? |
| 11:00 AM | Nicola Brunetti-Pierri, MD | University of Naples | Italy | Animal Models for PH3 |
| 11:15 AM | Ruth Belostotsky, PhD | Shaare Zedek Medical Center | Israel | Primary Hyperoxaluria Type 3 Metabolites: Are They Drivers of the Disease? |
| 11:30 AM | Tijn Rozemuller, MD, PhD | Amsterdam University Medical Center | The Netherlands | Why Did Nedosiran Not Work in PH2/PH3? |
| 11:45 AM | Moderator: Michael Somers, MD | Boston Children's Hospital | United States | Panel: All session speakers |
| 12:00 PM | Lunch Break | |||
| Session 3: Where We Are Today: Treatment of Primary Hyperoxaluria | ||||
| Chair: Mathieu Lemaire, MSc MDCM PhD FRCP(C) The Hospital for Sick Children Toronto Canada | ||||
| 1:00 PM | David Sas, DO | Mayo Clinic, Rochester | United States | Real World Use of siRNA |
| 1:15 PM | Mathieu Lemaire, MD MSc MDCM PhD FRCP(C) | The Hospital for Sick Children Toronto | Canada | Move Over, Liver Kidney-Alone Transplantation Takes Center Stage for PH1 - Thanks to siRNA Therapy |
| 1:30 PM | Laila Oubram, MD | Amsterdam University Medical Center | Netherlands | Optimizing Access to Lumasiran in Primary Hyperoxaluria Type 1 through a National Response-Guided Protocol |
| 1:37 PM | Kyle Wood, MD | University of Alabama, Birmingham | United States | Medical vs. Surgical: Where Do New Therapies Change the Game? |
| Oral Abstract Speed Round: | ||||
| 1:52 PM | Hadas Shasha - Lavsky, MD | Galilee Medical Center Israel | Israel | Lumasiran Treatment Outcomes in Infants with Primary Hyperoxaluria Type 1 |
| 1:59 PM | Laila Oubram, MD | Amsterdam University Medical Center | Netherlands | Pregnancy During Active Lumasiran Therapy in Primary Hyperoxaluria Type 1 |
| 2:06 PM | Georgia Mandrile, MD, PhD | AOU San Luigi Gonzaga | Italy | Functional and In Silico Characterization of Common AGXT Variants as Potential Modifiers of Primary Hyperoxaluria Type 1 |
| 2:13 PM | Moderator: Michelle Baum, MD | Boston Children's Hospital | United States | Panel: All session speakers |
| 2:30 PM | Coffee Break | |||
| Session 4: Managing Stone Burden: Urological Perspectives in Hyperoxaluria | ||||
| Chair(s): Thomas Chi, MD, MBA, FACS & Zham Okhunov, M.D. The University of Alabama, Birmingham & University of Utah United States | ||||
| 3:00 PM | Tom Chi, MD, MBA, FACS | University of Alabama, Birmingham | United States | Bridging the Gap: Urologys Role in Early Detection of Hyperoxaluria |
| 3:15 PM | Kevin Koo, MD | Mayo Clinic, Rochester | United States | What Are Endourologists Thinking? The Surgical Perspective on Complex Stones |
| 3:30 PM | Chen-Han Wilfred Wu, MD, PhD | University of Alabama Birmingham | United States | The Perspective of a Geneticist: Rare Stone Disease |
| Oral Abstract Speed Round: | ||||
| 3:45 PM | Mazzy Marcucci, BS | University of Utah | United States | Data-Driven Metabolic Phenotyping of Calcium Oxalate Nephrolithiasis Using Model-Based Clustering |
| 3:52 PM | Qazi Saqib Hamid, MD | Aga Khan University | Pakistan | Contribution of Primary Hyperoxaluria in a High-Risk Pakistani Cohort: Genetic and Phenotypic Insights |
| 3:59 PM | Moderator(s): Kyle Wood, MD | University of Alabama Medicine, Birmingham | United States | Audience Polling & Panelists: All session speakers |
| 4:15 PM | Kyle Wood, MD | University of Alabama Medicine, Birmingham | United States | Day 1 Closing |
| 4:20 PM | Welcome Reception / Poster Session | |||
| 5:20 PM | FINISH | |||
| Saturday, 27 June 2026 | ||||
| 8:00 AM | Registration & Poster Viewing | |||
| 8:45 AM | Kim Hollander | Oxalosis and Hyperoxaluria Foundation | United States | Day 2 Welcome |
| Session 5: Enteric Hyperoxaluria: What’s Next in Care and Treatment | ||||
| Chair(s): Jonathan Whittamore, PhD & Dirk Lange, PhD UT Southwestern Medical Center & University of British Columbia United States & Canada | ||||
| 8:50 AM | Elaine Worcester, MD | University of Chicago Medicine | United States | Outcomes of Enteric Hyperoxaluria – Stone and CKD Risk |
| 9:05 AM | John Knight, PhD | University of Alabama, Birmingham | United States | Enteric Hyperoxaluria: The Role of Oxalobacter Formigenes or Other Genetically Modified Bacteria |
| 9:20 AM | Lama Nazzal, MD | NYU Langone Health | United States | Targeting the Oxalobiome: Therapeutic Opportunities and Translational Challenges |
| 9:35 AM | Abraham Matar, MD | Dartmouth Geisel School of Medicine | United States | From Bariatric Surgery to Enteric Hyperoxaluria and Kidney Transplantation |
| 9:50 AM | John Lieske, MD | Mayo Clinic, Rochester | United States | What Happened to Enteric Hyperoxaluria Therapies? |
| 10:05 AM | Coffee Break | |||
| Session 6: Pipeline and Progress: Emerging Therapies in Primary Hyperoxaluria | ||||
| Chair(s): Sonia Fargue, MD, PhD & Monica Diaz Gavilan, PhD University of Alabama, Birmingham & University of Granada United States & Spain | ||||
| 10:30 AM | Monica Diaz Gavilan, PhD | University of Granada | Spain | Small Molecules– Targeting Protein Degradation in PH1 |
| 10:45 AM | Barbara Cellini, PhD | University of Perugia | Italy | Misfolding-Corrective Approaches in the Therapy of PH1 |
| 11:00 AM | Mervi E. Hyvönen, MD, PhD | Helsinki University Hospital and University of Helsinki | Finland | Gene Editing as a Therapeutic Strategy for Hyperoxaluria |
| 11:15 AM | Michelle Logsdon Gauvin, PhD | Stanford University | United States | Potential for mRNA Therapeutics in Primary Hyperoxaluria |
| 11:30 AM | Emmanuel Letavernier, MD, PhD | Tenun Hospital | France | Stiripentol: Set-up of the CRYSTAL Study |
| 11:40 AM | Marc De Broe, MD, PhD | Antwerp University Hospital | Belgium | The Role of the Gut for PH Treatment |
| 11:55 AM | John Lieske, MD | Mayo Clinic, Rochester | United States | redePHine: Advancing Gene Editing for Primary Hyperoxaluria Type 1 |
| 12:05 PM | Matthew Breeggemann, MD | University of California San Francisco | United States | YOLT-203, an In Vivo Gene-Editing Therapy for Primary Hyperoxaluria Type 1: Interim Results from Two Investigator-Initiated Trials |
| Oral Abstract Speed Round: | ||||
| 12:15 PM | Todd Lowther, PhD | Wake Forest University School of Medicine | United States | Inhibition of Hydroxyproline Dehydrogenase as a Therapy for Primary Hyperoxaluria |
| 12:22 PM | Lisa Ellerby, PhD | The Buck Institute | United States | N-Propargylglycine Restores Survival by Preventing Calcium Oxalate Stone Formation, Tubular Injury, and Kidney Dysfunction in a Lethal Mouse Model of Primary Hyperoxaluria Type 2 |
| 12:30 PM | Lunch Break | |||
| Session 7: From Data to Care: Registries & Centers of Excellence | ||||
| Chair: Shabbir Moochhala, MD, PhD, FRCPE Royal Free Hospital United Kingdom | ||||
| 1:30 PM | Kim Hollander, Executive Director | The Oxalosis and Hyperoxaluria Foundation | United States | Advancing Hyperoxaluria Through Global Collaboration Subtitle: Partnering with Patients, Clinicians, Researchers, and Advocates Worldwide |
| 1:40 PM | Bhaskar Somani, MD | University Hospital Southampton NHS Trust | United Kingdom | How to Create a Multidisciplinary Stone Teams |
| 1:55 PM | Matthew Breeggemann, MD | University of California San Francisco | United States | OHF Care Center Network: Advancing Global Care Together |
| 2:10 PM | Shabbir Moochhala, MD, PhD, FRCPE & John Lieske, MD | Royal Free Hospital & Mayo Clinic, Rochester | United States & United Kingdom | PH Registries: Collaboration in Action |
| Living with Hyperoxaluria: Global Patient and Caregiver Perspectives on Care, Access, and Treatment | ||||
| Moderator: Kevin Koo, MD Mayo Clinic United States | ||||
| 2:25 PM | Luigi (Italy) - Italian Hyperoxaluria Association Kristi (United States) - Finding A Way Maarten (the Netherlands) Zain (United Kingdom) Irene (Poland) - PH-Europe |
|||
| 2:50 PM | Coffee Break | |||
| Session 8: Global Perspectives in PH: Insights from Around the World | ||||
| Chair(s): Mini Michael, MD & Yaacov Frishberg, MD | ||||
| 3:20 PM | Velibor Tasic, MD, PhD, FESPN | University Children's Hospital | Macedonia | |
| 3:27 PM | Eva Flachsova, MD, PhD | Charles University | Czech Republic | |
| 3:34 PM | Naveen Soliman, MD | Cairo University | Egypt | |
| 3:41 PM | Faïza Meiouet, PhD | Royal Gendarmerie Medical Research and Analysis Laboratory | Morocco | |
| 3:48 PM | Marta Monteverde, MD | Hospital de Pediatría JP Garrahan | Argentina | |
| 3:55 PM | Maria Helena Vaisbich, MD, PhD | University of São Paulo School of Medicine – Clinics Hospital | Brazil | |
| 4:02 PM | Aditi Sinha, MD, PhD | All India Institute of Medical Sciences | India | |
| 4:09 PM | Seema Hashmi, MD | Sindh Institute of Urology and Transplantation | Pakistan | |
| 4:16 PM | Moderator(s): Mini Michael, MD & Yaacov Frishberg, MD | Texas Children's Hospital & Shaare Zedek Medical Center | United States & Israel | Panel: All Speakers |
| 4:30 PM | Kyle Wood, MD and Yaacov Frishberg, MD | University of Alabama, Birmingham & Shaare Zedek Medical Center | United States & Israel | Closing |
| 4:35 PM | FINISH | |||
| 7:00 PM | Trolley Transfer to Farewell Dinner | |||
| Farewell Dinner | ||||
